**Author details**

Dinara Sadykova1,2\*, Liliia Galimova1,2, Evgeniia Slastnikova1,2, Zulfiia Khabibrakhmanova1 and Natalya Guseva1,2

1 Kazan State Medical University, Kazan, Russian Federation

2 Children's Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Russian Federation

\*Address all correspondence to: sadykovadi@mail.ru

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**125**

2020-01-08]

*Statins for Children with Familial Hypercholesterolemia DOI: http://dx.doi.org/10.5772/intechopen.96007*

> Bruckerd E. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-2472. DOI:10.1093/

[7] Grundy S.M., Arai H., Barter P., Bersot T.P., Betteridge D.J., Carmena R. et al. An International Atherosclerosis

recommendations for the management of dyslipidemia – full report. J Clin Lipidol 2014;8:29-60. DOI: 10.1016/j.

Kusters D.M., Hof M.H., Groothoff J.W., de Groot E. et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. New Engl J Med 2019; 381(16): 1547-1556. DOI: 10.1056/

Society Position Paper: global

[8] Luirink I.K., Wiegman A.,

[9] Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425-2437. DOI: 10.1093/

[10] Clauss S.B., Holmes K.W., Hopkins P., Stein E., Cho M., Tate A.C. et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005; 116: 682-688. DOI: 10.1542/

[11] Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Baccer H., Buller H. R. et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized

eurheartj/ehx144

jacl.2013.12.005

nejmoa1816454

eurheartj/ehv157

peds.2004-2090

[1] Mathers C.D., Iburg B.K., Fat M.D., Shibuya K., Inoue M., Stein C. et al. Global Burden of Disease in 2002: data sources, methods and results. Global Programme on Evidence for Health Policy Discussion Paper No. 54 World Health Organization [Internet] December 2003. Available from: https:// www.who.int/healthinfo/paper54.pdf.

**References**

[Accessed: 2020-01-08]

ng1726

[2] Weiss L.A., Pan L., Abney M., Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nature Genetics 2006;38(2):218-222. DOI: 10.1038/

[3] Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B.,

CIR.0000000000000678

[4] Yezhov M.V., Bliznyuk S.A., Tmoyan N.A. Rozhkova T.A., Duplyakov D.V., Salchenko V.A. et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy

underperformance (RENESSANS). Rossiiskii kardiologicheskii zhurnal (Russian Journal of Cardiology) 2019;5:7-13. (in Russ.)] DOI: 10.15829/1560-4071-2019-5-7-13

[5] Classification and effects of statins. [Internet]. Available from: https:// noatero.ru/ru/klassifikaciya-i-effektystatinov (in Russ.). 2013. [Accessed:

[6] Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J.,

Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596-e646. DOI: 10.1161/ *Statins for Children with Familial Hypercholesterolemia DOI: http://dx.doi.org/10.5772/intechopen.96007*
